Comment on “gemcitabine, PI3kinase-Akt pathway inhibition and radiation in human glioma cell lines” by M.S. Elnaggar et al.1

The combination of gemcitabine, PI3K-Akt pathway inhibitors, and radiation in human glioma cell lines shows potential to enhance radiation sensitivity in aggressive brain tumors. Inhibiting the overactive PI3K-Akt pathway may increase tumor vulnerability to treatment. However, variability in respons...

Full description

Saved in:
Bibliographic Details
Published in:Medical oncology (Northwood, London, England) London, England), 2024-09, Vol.41 (10), p.248, Article 248
Main Authors: Balaji, M. B., Brahma, Neha, Vimal, S.
Format: Article
Language:English
Subjects:
Hematology
Internal Medicine
Letter to the Editor
Medicine
Medicine & Public Health
Oncology
Pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of gemcitabine, PI3K-Akt pathway inhibitors, and radiation in human glioma cell lines shows potential to enhance radiation sensitivity in aggressive brain tumors. Inhibiting the overactive PI3K-Akt pathway may increase tumor vulnerability to treatment. However, variability in responses among different glioma cell lines highlights the need for personalized approaches. Future research should focus on identifying biomarkers to tailor treatment for individual patients. Additionally, addressing safety concerns and the challenges of translating preclinical findings into clinical practice is crucial. Further studies should explore the therapy's molecular mechanisms and evaluate its clinical potential.
ISSN:1559-131X
1357-0560
1559-131X
DOI:10.1007/s12032-024-02503-5